Market Forecast
Registering a CAGR of 10.50%, the Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million by 2025.
As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world.
The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample request/8319
Market Influencer
The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.
Segmentation
By Drugs:
- Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
- Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
- Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
- Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.
By Route of Administration:
- Oral: The segment is expected to hold the largest market share.
- Intravenous: The segment is expected to grow at the fastest CAGR.
- Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
- Others: Subcutaneous and intramuscular routes of administration.
By Distribution Channel:
- Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
- Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
- Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.
By Region
- Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
- Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
- Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.
- Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
- Kamada Pharmaceuticals (Israel)
- CSL Behring LLC (US)
- Grifols, S.A. (Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- AstraZeneca (UK)
- Vectura Group plc (UK)
- Pfizer Inc. (US)
- Mylan Inc. (US)
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Global Alpha-1 Antitrypsin Deficiency Treatment Market Research Report: By Drugs (Alpha-1 Proteinase Inhibitor, Bronchodilators, Steroids, Others), By Route of Administration (Oral, Intravenous, Inhalation, Others) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) – Forecast to 2025Market Highlights:Registering a CAGR of 10.50%, the Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million by 2025.As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide.
The disorder is found to affect populations in all the regions of the world.The market is dominated by numerous established players.
The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions.
For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.Market InfluencerThe prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market.
Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/8319SegmentationBy Drugs:Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.By Route of Administration:Oral: The segment is expected to hold the largest market share.Intravenous: The segment is expected to grow at the fastest CAGR.Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.Others: Subcutaneous and intramuscular routes of administration.By Distribution Channel:Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.Access Report Details @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319Key PlayersKamada Pharmaceuticals (Israel)CSL Behring LLC (US)Grifols, S.A. (Spain)Takeda Pharmaceutical Company Limited (Japan)GlaxoSmithKline plc (UK)Boehringer Ingelheim GmbH (Germany)AstraZeneca (UK)Vectura Group plc (UK)Pfizer Inc. (US)Mylan Inc. (US) About Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.Contact Us:Market Research Future Phone: +1 646 845 9312Email: [email protected]
Alpha-1 Antitrypsin Deficiency Treatment Market Research Report: By Drugs (Alpha-1 Proteinase Inhibitor, Bronchodilators, Steroids), Route of Administration (Oral, Intravenous, Inhalation) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) - Forecast to 2027Market ForecastRegistering a CAGR of 10.50%, the Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million by 2025.As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide.
The disorder is found to affect populations in all the regions of the world.The market is dominated by numerous established players.
The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions.
For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.Market InfluencerThe prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market.
Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8319 SegmentationBy Drugs:Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.By Route of Administration:Oral: The segment is expected to hold the largest market share.Intravenous: The segment is expected to grow at the fastest CAGR.Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.Others: Subcutaneous and intramuscular routes of administration.By Distribution Channel:Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.By RegionAmericas: The region holds the largest share of the market.
The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe.
Transparency Market Research has published a new report titled, ‘Alpha 1 Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
According to the report, the global Alpha 1 Antitrypsin Deficiency Treatment market was valued at around US$ 1.4 Bn in 2018 and is projected to grow at a CAGR of 10.1% from 2019 to 2027.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=13214OverviewAlpha-1 antitrypsin (AAT) deficiency is a condition in which the body does not make enough of AAT, a protein that protects the lungs and liver from damage.Alpha-1 Antitrypsin is a type of protein belongs to the class protease inhibitor.
This protein is produced in the liver and is primarily functions to protect the lungs and liver from the harmful effects of other protein in the body.The AAT deficiency is genetic disorder that causes low and defective production of AAT proteins in liver which results in the accumulation of AAT in the liver and low amount of it in blood stream.Patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases (COPD), and emphysema diseases.The AAT deficiency disease can be treated using different therapeutic methods such as augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and other treatment methods.Rise in incidence and prevalence of respiratory diseases across the world is the major factor to drive the global market.
North America dominated the global Alpha 1 Antitrypsin Deficiency Treatment market in 2018 and anticipated to dominate during the forecast period.Request COVID Analysis on Alpha 1 Antitrypsin Deficiency Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=13214 Rise in prevalence of respiratory diseases to Drive MarketHigher incidence & prevalence of chronic respiratory diseases across the world is the major driver for the growth of global Alpha 1 Antitrypsin Deficiency Treatment market.Improved technology for production and purification methods and growing prescription number for combination therapies are some of the major factors fuelling the growth of global Alpha 1 Antitrypsin deficiency treatment marketFor instance, the PlasmaTech SDF (salt diafiltration) process is a plasma-based platform developed for commercial production of orphan protein therapeutics such as alpha-1 antitrypsinHigher R spend in asthma and COPD treatment and rising awareness programs in developing countries are some of the key driving factors for the growth of global Alpha 1 Antitrypsin deficiency treatment market.Augmentation therapy Segment to Dominate MarketBased on treatment, the global Alpha 1 Antitrypsin deficiency treatment market has been segmented into augmentation therapy, bronchodilator, corticosteroids, oxygen therapy, and othersAugmentation therapy segment is further sub-segmented into Aralast, Prolastin, Zamaira/ Respreeza, and GlassiaAugmentation therapy segment is accounted for the major market share in 2019 and during the forecast period owing to high acceptance of the therapy in developed regions such as the U.S. and Europe.Request Customization on Alpha 1 Antitrypsin Deficiency Treatment Market Report –https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=13214Inhalation Segment – More Promising Route of Administration segmentIn terms of route of administration, the global Alpha 1 Antitrypsin deficiency treatment market has been divided into parenteral, inhalation, and oral.Inhalation segment is more lucrative segment during the forecast period owing to increasing focus on R for developing inhalation formulation of existing alpha-1 antitrypsin.
The region is also home to several key players such as CSL Behring LLC which boosts the market in this region.For instance, as per Centers for Disease Control and Prevention (CDC) estimates, COPD is responsible for about700,000 hospitalizations annually in the U.S.The Alpha 1 Antitrypsin Deficiency Treatment market in Europe is anticipated to expand at a higher CAGR from 2019to 2027.
This can be ascribed to High adoption of novel treatment methods for the well-being of the rapidly growing population with immune system disorders in the region.Buy Alpha 1 Antitrypsin Deficiency Treatment Market Report –https://www.transparencymarketresearch.com/checkout.php?rep_id=13214=SCompetitive LandscapeThe global Alpha 1 Antitrypsin Deficiency Treatment market is consolidated as few players hold major market share in global market.
